GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (FRA:9UA) » Definitions » Momentum Rank

NervGen Pharma (FRA:9UA) Momentum Rank : 0 (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NervGen Pharma Momentum Rank?

NervGen Pharma has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


NervGen Pharma Momentum Rank Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma (FRA:9UA) Business Description

Traded in Other Exchanges
Address
2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (FRA:9UA) Headlines

No Headlines